Potential strategies utilised by papillomavirus to evade host immunity

Immunological Reviews

Volumn 168, Issue , 1999, Pages 131-142

  Frazer, Ian H ^a   Thomas, Ranjeny ^a   Zhou, Jian ^a   Leggatt, Graham R ^a   Dunn, Linda ^a,c   McMillan, Nigel ^a   Tindle, Robert W ^b   Filgueira, Luis ^c   Manders, Peter ^a   Barnard, Paula ^a   Sharkey, Michael ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; VIRUS PROTEIN;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CELL PROLIFERATION; CODON; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENCE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE; LYSIS; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN DEFECT; VIRUS CAPSID; VIRUS INFECTION;

ANIMALS; EPITHELIAL CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; INTERFERON-ALPHA; KERATINOCYTES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR VIRUS INFECTIONS; VIRAL PROTEINS;

EID: 0033061881     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01288.x     Document Type: Article

References (82)

1. 1. Zur Hausen H, de Villiers EM, Gissmann L. Papillomavirus infections and human genital cancer. Gynecol Oncol 1981;12:S124-S128.
2. 2. Frazer IH, Medley G, Crapper RM, Brown TC, Mackay IR. Association between anorectal dysplasia, human papillomavirus, and human immunodeficiency virus infection in homosexual men. Lancet 1986;2(8508):657-660.
3. 3. Melbye M, et al. Immune status as a determinant of human papillomavirus detection and its association with anal epithelial abnormalities. Int J Cancer 1990;46:203-206.
4. 4. Cancer report. In: Shiel AGR, Disney APS, eds. ANZDATA Report 1991. Adelaide, South Australia: Australia and New Zealand Dialysis and Transplant Registry; 1991. p. 100-108.
5. 5. Coleman N, et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994;102:768-774.
6. 6. Leigh IM, Glover MT. Cutaneous warts and tumours in immunosuppressed patients. J R Soc Med 1995;88:61-62.
7. 7. Rudlinger R, Smith IW, Bunney MH, Hunter JA. Human papillomavirus infections in a group of renal transplant recipients. Br J Dermatol 1986;115:681-692.
8. 8. Carter JJ, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996;174:927-936.
9. 9. Durst M, Bosch FX, Glitz D, Schneider A, Zur Hausen H. Inverse relationship between human papillomavirus (HPV) type 16 early gene expression and cell differentiation in nude mouse epithelial cysts and tumors induced by HPV-positive human cell lines, J Virol 1991;65:796-804.
10. 10. Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, Broker TR. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 1992;23:117-128.
11. 11. Ruesch MN, Stubenrauch F, Laimins LA. Activation of papillomavirus late gene transcription and genome amplification upon differentiation in semisolid medium is coincident with expression of involucrin and transglutaminase but not keratin-10. J Virol 1998;72:5016-5024.
12. 12. Crum CP, Nagai N, Levine RU, Silverstein S. In situ hybridization analysis of HPV 16 DNA sequences in early cervical neoplasia. Am J Pathol 1986;123:174-182.
13. 13. Greenfield I, Nickerson J, Penman S, Stanley M. Human papillomavirus 16 E7 protein is associated with the nuclear matrix. Proc Natl Acad Sci USA 1991;88:11217-11221.
14. 14. Doorbar J, et al. Characterisation of events during the late stages of HPV 16 infection in vivo using high-affinity synthetic Fabs to E4. Virology 1997;238:40-52.
15. 15. Frazer IH. Immunology of papillomavirus infection. Curr Opin Immunol 1996;8:484-491.
16. 16. Tindle RW, Frazer IH. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation. Curr Top Microbiol Immunol 1994;186:217-253.
17. 17. Jochmus-Kudielka I, et al. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst 1989;81:1698-1704.
18. 18. Bachmann MF, Zinkernagel RM, Oxenius A. Immune responses in the absence of costimulation: viruses know the trick. J Immunol 1998;161:S791-S794.
19. 19. Baker CC, Howley PM. Differential promoter utilization by the bovine papillomavirus in transformed cells and productively infected wart tissues. EMBO J 1987;6:1027-1035.
20. 20. Grassmann K, Rapp B, Maschek H, Petry KU, Iftner T. Identification of a differentiation-inducible promoter in the E7 open reading frame of human papillomavirus type 16 (HPV-16) in raft cultures of a new cell line containing high copy numbers of episomal HPV 16 DNA. J Virol 1996;70:2339-2349.
21. 21. Barksdale SK, Baker CC. Differentiation-specific alternative splicing of bovine papillomavirus late mRNAs. J Virol 1995;69:6553-6556.
22. 22. Kennedy IM, Haddow JK, Clements JB. Analysis of human papillomavirus type 16 late mRNA 3' processing signals in vitro and in vivo. J Virol 1990;64:1825-1829.
23. 23. Furth PA, Baker CC. An element in the bovine papillomavirus late 3' untranslated region reduces polyadenylated cytoplasmic RNA levels. J Virol 1991;65:5806-5812.
24. 24. Sokolowski M, Zhao CP, Tan W, Schwartz S. AU-rich mRNA instability elements on human papillomavirus type 1 late mRNAs and c-fos mRNAs interact with the same cellular factors. Oncogene 1997;15:2303-2319.
25. 25. Furth PA, Choe W-T, Rex JH, Byrne JC, Baker CC. Sequences homologous to 5' splice sites are required for the inhibitory activity of papillomavirus late 3' untranslated regions. Mol Cell Biol 1994;14:5278-5289.
26. 26. Schwartz S. Cis-acting negative RNA elements on papillomavirus late mRNAs. Semin Virol 1998;8:291-300.
27. 27. Stubenrauch F, Leigh IM, Pfister H. E2 represses the late gene promoter of human papillomavirus type 8 at high concentrations by interfering with cellular factors. J Virol 1996;70:119-126.
28. 28. Hagensee ME, Yaegashi N, Galloway DA. Self assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993;67:315-322.
29. 29. Kirnbaner R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992;89:12180-12184.
30. 30. Volpers C, Schirmacher P, Streeck RE, Sapp M. Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. Virology 1994;200:504-512.
31. 31. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 161.1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion like particles. Virology 1991,185:251-257.
32. 32. Jansen KU, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus like particles protects rabbits from CRPV induced papilloma formation. Vaccine 1995;13:1509-1514.
33. 33. Sasagawa T, et al. Synthesis and assembly of virus like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 1995;206:126-135.
34. 34. Smith DW. Problems of translating heterologous genes in expression systems: the role of tRNA. Biotechnol Prog 1996;12:417-422.
35. 35. Strauss EG, Strauss JH, Levine AJ. Virus evolution. In: fields BN, Knipe DM, howley PM, eds. Virology. 3rd ed. Philadelphia: Lippincott-Raven; 1995. p. 153-171.
36. 36. Zhou J, Liu WJ, Peng SW, Sun X-Y, Frazer IH. Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J Virol 1999;73:4972-4982.
37. 37. Spriggs MK. One step ahead of the game: viral immunomodulatory molecules. Annu Rev Immunol 1996;14:101-130.
38. 38. Gooding LR. Virus proteins that counteract host immune defenses. Cell 1992;71:5-7.
39. 39. Vousden K. Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. FASEB J 1993;7:872-879.
40. 40. Evander M, Frazer IH, Payne E, Qi YM, Hengst K, McMillan NA. Identification of the α6 integrin as a candidate receptor for papillomaviruses. J Virol 1997;71:2449-2456.
41. 41. Price AA, Cumberbatch M, Kimber I, Ager A. α6 integrins are required for Langerhans cell migration from the epidermis. J Exp Med 1997;186:1725-1735.
42. 42. Borkowski TA, Letterio JJ, Farr AG, Udey MC. A role for endogenous transforming growth factor β1 in Langerhans cell biology: the skin of transforming growth factor β1 null mice is devoid of epidermal Langerhans cells. J Exp Med 1996;184:2417-2422.
43. 43. Geissmann F, Prost C, Monnet JP, Dy M, Brousse N, Hermine O. Transforming growth factor b1 in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells. J Exp Med 1998;187:961-966.
44. 44. Ulmer JB, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-1749.
45. 45. Xu L, et al. Immunization for Ebola virus infection. Nat Med 1998;4:37-42.
46. 46. Imai Y, Matsushima Y, Sugimura T, Terada M. Purification and characterization of human papillomavirus type 16 E7 protein with preferential binding capacity to the underphosphorylated form of retinoblastoma gene product. J Virol 1991;65:4966-4972.
47. 47. Lambert PF, Pan H, Pitot H, Liem A, Jackson M, Griep AE. Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice. Proc Natl Acad Sci USA 1993;90:5583-5587.
48. 48. Casares S, Inaba K, Brumeanu TD, Steinman RM, Bona CA. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med 1997;186:1481-1486.
49. 49. Ulmer JB, et al. Expression of a viral protein by muscle cells in vivo induces protective cell mediated immunity. Vaccine 1997;15:839-841.
50. 50. Vilcek J, Sen GC. Interferons and other cytokines. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology, 3rd ed. Philadelphia: Lippincott-Raven; 1996. p. 375-399.
51. 51. Gutch MJ, Reich NC. Repression of the interferon signal transduction pathway by the adenovirus E1A oncogene. Proc Natl Acad Sci USA 1991;88:7913-7917.
52. 52. Kalvakolanu DV, Bandyopadhyay SK, Harter ML, Sen GC. Inhibition of interferon-inducible gene expression by adenovirus E1A proteins: block in transcriptional complex formation. Proc Natl Acad Sci USA 1991;88:7459-7463.
53. 53. Stark G, Kerr IM. Intereferon dependent signalling pathways: DNA elements, transcription factors, mutations and effects of viral proteins. J Interferon Res 1992;12:147-151.
54. 54. Woodworth CD, Lichti U, Simpson S, Evans CH, DiPaolo JA. Leukoregulin and γ-interferon inhibit human papillomavirus type 16 gene transcription in human papillomavirus-immortalized human cervical cells. Cancer Res 1992;52:456-463.
55. 55. Arany I, Goel A, Tyring SK. Interferon response depends on viral transcription in human papillomavirus-containing lesions. Anticancer Res 1995;15:2865-2869.
56. 56. Ronco LV, Karpova AY, Vidal M, Howley PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998;12:2061-2072.
57. 57. Straight SW, Hinkle PM, Jewers RJ, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol 1993;67:4521-4532.
58. 58. Straight SW, Herman B, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J Virol 1995;69:3185-3192.
59. 59. Stoppler H, Kirchhoff T, Kartenbeck J, Gissmann L, Alonso A. Influence of human papillomavirus type 16 gene expression on in vitro differentiation of the human teratocarcinoma cell line 2102Ep. Mol Carcinog 1996;16:109-114.
60. + cells and persistence of viral DNA after regression. J Virol 1997;71:5540-5548.
61. 61. Symington FW, Santos EB. Lysis of human keratinocytes by allogeneic HLA class I-specific cytotoxic T cells. Keratinocyte ICAM-1 (CD54) and T cell LFA-1 (CD11a/CD18) mediate enhanced lysis of IFN-γ-treated keratinocytes. J Immunol 1991;146:2169-2175.
62. 62. Symington FW, Santos EB. Recognition of keratinocytes by cytotoxic T cells specific for conventional HLA class-I alloantigen. J Invest Dermatol 1990;95:224-228.
63. 63. De BM, Van EC, Kempenaar J, Ponec M, Goulmy E. A new sensitive assay for measurement of cell-mediated cytotoxicity to intact layers of cultured human keratinocytes. J Immunol Methods 1990;127:117-122.
64. 64. Van-Els CA, de-Bueger MM, Kempenaar J, Ponec M, Goulmy E. Susceptibility of human male keratinocytes to MHC-restricted H-Y-specific lysis. J Exp Med 1989;170:1469-1474.
65. 65. Niederwieser D, et al. IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses. J Immunol 1988;140:2556-2564.
66. 66. Cairns BA, DeSerres S, Matsui M, Frelinger JA, Meyer AA. Cultured mouse keratinocyte allografts prime for accelerated second set rejection and enhanced cytotoxic lymphocyte response. Transplantation 1994;58:67-72.
67. 67. Oukka M, et al. Major histocompatibility complex class I presentation of exogenously acquired minor alloantigens initiates skin allograft rejection. Eur J Immunol 1997;27:3499-3506.
68. 68. Dunn LA, et al. Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal. Virology 1997;235:94-103.
69. 69. Chambers MA, Wei Z, Coleman N, Nash AA, Stanley MA. "Natural" presentation of human papillomavirus type-16 E7 protein to immunocompetent mice results in antigen-specific sensitization or sustained unresponsiveness. Eur J Immunol 199;24:738-745.
70. 70. Doan T, et al. Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes. Virology 1998;244:352-364.
71. 71. Frazer IH, et al. Split tolerance to a viral antigen expressed in thymic epithelium and kerannocytes. Eur J Immunol 1998;28:2791-2800.
72. + T cell activation and IFN-γ production. J Immunol 1998;161:2848-2855.
73. 73. Sayers TJ, et al. Molecular mechanisms of immune mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas mediated pathways in lysis by NK and T cells. J Immunol 1998;161:3957-3965.
74. 74. Ressing ME, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen A*0201-restricted E7-encoded epitope. Cancer Res 1996;56:582-588.
75. 75. Nimako M, Fiander AN, Wilkinson GW, Borysiewicz LK, Man S. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res 1997;57:4855-4861.
76. 76. Borysiewicz LK, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-1527.
77. 77. Antoniou A, et al. T cell tolerance and activation to a transgene-encoded tumor antigen. Eur J Immunol 1996;26:1094-1102.
78. 78. Herber R, Liem A, Pitot H, Lambert PF. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J Virol 1996;70:1873-1881.
79. 79. Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 1991;173:1007-1015.
80. 80. Bal V, et al. Antigen presentation by keratinocytes induces tolerance in human T cells. Eur J Immunol 1990;20:1893-1897.
81. 81. Alferink J, Tafuri A, Vestweber D, Hallmann R, Hämmerling GJ, Arnold B. Control of neonatal tolerance to tissue antigens by peripheral T cell trafficking. Science 1998;282:1338-1341.
82. 82. Heath WR, Kurts C, Miller JFAP, Carbone FR. Cross-tolerance: A pathway for inducing tolerance to peripheral tissue antigens. J Exp Med 1998;187:1549-1553.